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OBJECTIVES To assess the effect of nonionic versus ionic contrast media on abrupt vessel closure and major
ischemic complications after coronary angioplasty.
BACKGROUND There is a continuous debate about the “thrombogenic potential” of nonionic contrast media.
The results of both in vitro and in vivo investigations are incongruent.
METHODS We prospectively evaluated the outcomes of 2,000 patients undergoing percutaneous
transluminal coronary angioplasty (PTCA). According to a randomized, double-blind
protocol, they received either iomeprol (nonionic; n 5 1,001) or ioxaglate (ionic; n 5 999).
Intracoronary thrombus before PTCA was found more often in the iomeprol group (4.2% vs
2.7%, p 5 0.04). No other significant differences between both groups were observed with
regard to pre-PTCA clinical and angiographic characteristics.
RESULTS The frequency of reocclusions necessitating repeat angioplasty occurring either in laboratory
(2.9% with iomeprol and 3.0% with ioxaglate) or out of laboratory (3.1% vs 4.1%) was not
significantly different. The rate of major ischemic complications was also comparable after
both contrast media (emergency bypass surgery: 0.8% vs 0.7%, myocardial infarction: 1.8 vs
2.0%, cardiac death during hospital stay: 0.2% vs 0.2%). In the iomeprol group, more patients
had dissections post-PTCA (30.2% vs 25.0%, p 5 0.01) and more patients received
intracoronary stents (31.6% vs 25.7%, p 5 0.004). Allergic reactions requiring treatment
occurred only in the ioxaglate group (0.0% vs 0.9%, p 5 0.002).
CONCLUSIONS The nonionic contrast medium was not associated with a higher rate of abrupt vessel closure
requiring repeat angioplasty, or major ischemic events. These data suggest that nonionic contrast
media do not increase the risk of thrombotic complications in patients undergoing coronary
interventions. (J Am Coll Cardiol 1999;33:395–402) © 1999 by the American College of
Cardiology
Under in vitro conditions, contrast media have multiple
effects on both the intrinsic and extrinsic pathway of blood
coagulation, thrombocyte function and vascular endothe-
lium. All contrast agents act as anticoagulants to a variable
extent. Nonionic contrast media have a markedly lower
inhibition of the intrinsic pathway (1–8). The discussion
regarding the relationship between nonionic contrast media
and thrombotic complications began when Robertson ob-
served blood clot formation in angiographic syringes filled
with a mixture of nonionic contrast medium and blood that
were left stagnant for 30 min (9). Reports of thrombotic
events occurring during diagnostic coronary angiography
with nonionic contrast media have fueled the debate with
additional concern (10). In an editorial published in 1990,
Fareed et al. even postulated a “thrombogenic potential” of
nonionic contrast media (11).
This has led to the concern that thrombus formation,
abrupt vessel closure and major adverse cardiac events after
coronary angioplasty may occur more often with nonionic
than with ionic agents. Thus far, six randomized studies
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comparing the effects of nonionic versus ionic contrast
media have been published (12–17). However, there were
no significant differences observed in the incidence emer-
gent bypass surgery, myocardial infarction and cardiac death
between both types of contrast media. We have designed a
trial to investigate prospectively whether the so called
“thrombogenic potential” of nonionic contrast media may
affect angiographic and clinical outcomes in patients under-
going both routine and high-risk coronary angioplasty.
METHODS
Patients and contrast media. All patients presenting for
either elective or emergency coronary angioplasty at a single
institution were considered eligible for randomization un-
less they had a known history of allergic reactions to
iodinated contrast media. The protocol had been approved
by the institutional review board on clinical research, and
informed written consent was obtained from each patient
before enrollment. Over a 14-month period (from January
1996 to February 1997), a total of 2,458 coronary interven-
tions were performed in our catheterization laboratory.
During that period, 2,000 patients were randomized to
receive either iomeprol (Imeron 350, 350 mg iodine/ml,
0.62 osmol/kg; Bracco-Byk-Gulden GmbH, Konstanz,
Germany; n 5 1001), or ioxaglate (Hexabrix 320, 320 mg
iodine/ml, 0.60 osmol/kg; Guerbet GmbH, Sulzbach/
Taunus, Germany; n 5 999). Of these 2,000 patients, 1,626
presented for elective interventions. Urgent PTCA (within
24 h) was performed in 346 patients with unstable angina.
Emergent PTCA (within 1 h) was performed in 32 patients
with acute myocardial infarction. The remaining 458 pa-
tients were not included because of known contrast allergy
(n 5 131) or because they refused randomization (n 5 327).
The baseline clinical data for each patient were recorded on
standard forms.
Study protocol. During the entire study period, patients
were randomized day by day (Monday through Sunday)
before catheterization using a computer-generated random-
ization list kept by the chief technician (I.E.) in the
laboratory. Coronary interventions were performed by seven
interventional cardiologists (R.E., W.A.F., H.M., D.S.,
R.S., H.S., H.F.S.), who were blinded to the contrast agent
by wrapping the bottle with an opaque plastic bag. The
patients who were not on oral aspirin before PTCA received
an intravenous injection of 500 mg soluble ASA before the
intervention. Routinely, the patients received an intraarterial
bolus injection of 20,000 units of heparin. Patients who had
an intravenous 1,000-unit/h infusion of heparin before
PTCA received a bolus of only 10,000 units. An additional
bolus of 10,000 units of heparin was administered when
considered necessary by the catheterization physician. The
activated clotting time was not determined routinely.
PTCA was performed using standard techniques through 6-
and 8-French guiding catheters. The use of adjunctive
techniques (intracoronary fibrinolysis, rotational and direc-
tional atherectomy, laser) was left to the discretion of the
operator. Glycoprotein IIb/IIIa inhibitors were not utilized
during any of these procedures. The criteria for the use of
either primary (eg, restenosis, major dissection, recoil) or
bail-out stent implantation were not predefined as part of
the initial study design. The clinical decision for the use of
stents was left to the discretion of the operator. Stent
implantations were performed with high-pressure balloon
inflations, and thereafter 250 mg ticlopidine twice daily was
prescribed for 4 weeks, routinely. For abrupt vessel closure,
urgent repeat coronary angioplasty was, in general, the
initial strategy. Pre- and postprocedural electrocardiograms
(ECGs) were recorded in all patients.
Procedural variables. The number of attempted lesions
(n), fluoroscopy time (min), heparin dose (IU/kg) and the
volume of contrast medium used (ml) were recorded to-
gether with eventual side effects requiring specific treat-
ment.
Angiographic analysis. Coronary angiography was per-
formed before and after balloon inflation, using at least two
identical views for comparison. In grading the complexity of
the lesions, the ACC/AHA (American College of Cardiology/
American Heart Association) system of Ellis et al. (18) was
used. The angioplasty procedure was defined as successful
when the residual stenosis was less than 50% by visual
assessment. Two independent operators reviewed the films for
the pre- and postprocedural degree of stenosis, elastic recoil
(immediate success after balloon inflation but residual stenosis
.50% on the following angiograms), dissection, intracoronary
thrombus and abrupt vessel closure. In case of disagreements
between the two operators, the results were discussed and a
third operator made the decision, when necessary.
Clinical endpoints. Primary endpoints were abrupt vessel
closure occurring either during the percutaneous translumi-
nal coronary angioplasty (in laboratory), defined as an
intracoronary filling defect after balloon inflation causing
total occlusion of the vessel and necessitating reintroduction
of the balloon catheter, or after the procedure (out of
Abbreviations and Acronyms
ASA 5 acetyl salicylic acid
CK 5 creatine kinase
Closure i.lab. 5 abrupt vessel closure in laboratory
Closure o.lab. 5 abrupt vessel closure out of laboratory
ECG 5 electrocardiogram
g.w. 5 guidewire
i.c. 5 intracoronary
MACE 5 major adverse cardiac events
MI 5 myocardial infarction
NS 5 not significant
Ref. 5 reference
PTCA 5 percutaneous transluminal coronary
angioplasty
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laboratory), defined as an episode of ischemic chest pain
and/or ST-segment changes, followed by the same angio-
graphic finding. Secondary endpoints were major adverse
cardiac events occurring during the patient’s hospital stay for
the PTCA procedure: emergency coronary bypass surgery,
defined as the need for operative revascularization on the
same day as the procedure for unstable or ongoing myocar-
dial ischemia; myocardial infarction, defined either as an
increase of the creatine kinase level above three times the
upper limit of normal for our laboratory or the appearance of
new Q-waves after the procedure; and cardiac death that
occurred during the hospitalization.
Statistical analysis. Assuming an event rate of 5% in the
control group, a difference of more than 3.2% in the other
group would be detected to be statistically significant with a
sample size of 1,000 patients in each arm (p ,0.05, power,
0.80). Data entry and data analysis were carried out using
the software package SAS. Statistical comparison of differ-
ences between both groups were carried out using the Fisher
exact test. A subgroup analysis was performed in patients
with stable versus unstable coronary syndromes as well as in
patients who received intracoronary stents versus patients
who did not, although intracoronary stenting had not been
predefined as an endpoint in the initial study design. For the
primary and secondary clinical endpoints, the point esti-
mates and 95% confidence limits among the patient sub-
groups were calculated.
RESULTS
Patients, indications for PTCA and lesion morphology.
The baseline demographic data, the indication for PTCA
and the morphology of target lesions in the nonionic and
ionic contrast medium groups were similar. However, there
were more patients with intracoronary thrombus pre-PTCA
in the nonionic group (Table 1).
Procedural variables and angiographic outcomes.
Atherectomy, both rotational and directional, and laser were
used in less than 3% of patients in either contrast medium
group. The fluoroscopy time and the contrast dose were
comparable in the nonionic and the ionic group. The
heparin dose was higher in patients randomized to receive
the ionic contrast medium. In the nonionic group, more
coronary lesions were attempted and more patients received
thrombolytics. After balloon inflation, dissections and elas-
tic recoil were observed significantly more often in patients
randomized to the nonionic contrast medium. The inci-
dence of intracoronary thrombi decreased in the nonionic
group from 4.2% before PTCA to 2.8% after PTCA, but
increased from 2.7% to 2.8% with the ionic contrast
medium. Significantly more patients randomized to the
nonionic contrast medium group received coronary stents.
The success rate and the residual stenosis were similar in
both groups (Table 2).
Adverse side effects. Allergic symptoms requiring therapy
with either H1- and H2-antagonists and prednisolone or
intravenous volume substitution and catecholamines were ob-
served only in patients (n 5 9) who were randomized to receive
ioxaglate (bronchospasm 5 1; vomiting 5 1; rash 5 3;
hypotension 5 4). The difference between both contrast media
groups was significant (p 5 0.002). Arrythmia requiring
treatment (atropine, antiarrythmic drugs, defibrillation) oc-
curred in two patients in the nonionic group (atrial fibrillation)
compared with eight patients in the ionic group (bradycardia 5
4; atrial fibrillation 5 2; ventricular fibrillation 5 2).
Table 1. Baseline Characteristics, Indication for PTCA and Lesion Morphology
Iomeprol
(n 5 1,001)
Ioxaglate
(n 5 999) p
Baseline Characteristics
Age (years) (mean 6 SD) 63.2 6 10.0 63.3 6 10.2 0.75
Male patients (%) 80.8 78.5 0.20
Weight (kg) (mean 6 SD) 79.6 6 12.5 78.9 6 12.2 0.19
Prior myocardial infarction (%) 10.9 9.5 0.34
Prior bypass surgery (%) 9.1 8.1 0.47
Indication for PTCA
Acute myocardial infarction (%) 1.6 1.6 1.00
Unstable angina (%) 17.9 16.7 0.52
Stable angina (%) 59.3 62.1 0.18
Silent ischemia (%) 14.5 14.2 0.85
Restenosis (%) 14.0 12.0 0.54
Lesion Morphology
ACC/AHA Type A (%) 31.0 31.8 0.70
ACC/AHA Type B (%) 47.5 47.2 0.93
ACC/AHA Type C (%) 21.5 21.0 0.73
Thrombus before PTCA (%) 4.2 2.7 0.04
Dissection before PTCA (%) 1.3 1.4 0.85
Total occlusion (%) 12.4 12.4 1.00
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Angiographic and clinical endpoints. There were no sig-
nificant differences among both contrast medium groups.
The primary endpoints were reached in 60 patients (6.0%)
randomized to receive the nonionic contrast medium and in
71 patients (7.1%) in the ionic contrast medium group.
Major adverse cardiac events were observed in 23 patients
(2.3%) receiving the nonionic as well as the ionic contrast
medium. There were two noncardiac deaths during the
same hospital stay in the nonionic group. Both patients died
after abdominal cancer surgery, 21 and 31 days after
uncomplicated and successful coronary angioplasty, respec-
tively (Table 3).
Patients with stable versus unstable symptoms. There
were no significant differences between both contrast me-
dium groups with regard to baseline demographic data,
target vessels and target lesion morphology, except for the
higher presence of thrombus before PTCA in the nonionic
group (1.6% vs 1.0% in stable patients, and 10.5% vs 7.7%
in unstable patients). Intracoronary stenting was performed
more often in the nonionic group (28.6% vs 24.8% in stable
patients, and 44.0% vs 29.8% in unstable patients). How-
ever, more dissections were observed after balloon angio-
plasty in patients randomized to receive the nonionic agent
(28.6% vs 23.2% in stable patients, and 36.8% vs 33.1% in
unstable patients). Between both contrast media, there were
no significant differences with regard to abrupt closure in
laboratory, abrupt closure out of laboratory or major adverse
cardiac events neither in patients with stable nor in patients
with unstable symptoms (Figs. 1–3).
Patients without and with intracoronary stents. No sig-
nificant differences between both contrast medium
groups with regard to baseline demographic data, target
vessels, target lesion morphology and procedural variables
were observed in the patients without stents. The inci-
dence of post-PTCA thrombus, dissection and recoil was
1.8%, 14.2% and 1.6% in the nonionic, as compared with
2.0%, 10.6% and 1.2% in the ionic contrast medium
group. In the patients who had received intracoronary
stents, the incidence of pre-PTCA thrombus was 6.1% in
the nonionic and 3.6% in the ionic contrast medium
group. After balloon angioplasty (before stent implanta-
tion), the incidence of thrombus, dissection and recoil
was 5.1%, 64.9% and 11.1% in the nonionic, as compared
with 5.1%, 66.5% and 7.4% in the ionic contrast medium
group. No significant differences between both contrast
media groups were found with regard to abrupt closure in
laboratory, abrupt closure out of laboratory or major
adverse cardiac events neither in patients without nor in
patients with intracoronary stents (Figs. 1–3).
Table 2. Procedural Variables and Angiographic Outcomes
Iomeprol
(n 5 1,001)
Ioxaglate
(n 5 999) p
Procedural Variables
Attempted coronary lesions 1,256 1,185
Fluoroscopy time (min) (mean 6 SD) 12.3 6 11.4 12.2 6 11.4 0.16
Heparin dose (IU/kg bw) (mean 6 SD) 254 6 47 258 6 44 0.03
Contrast dose (ml/kg bw) (mean 6 SD) 2.25 6 1.0 2.28 6 1.0 0.52
Intracoronary thrombolytics (%) 1.4 0.4 0.03
Stent implantation (%) 31.6 25.7 0.004
Angiographic Outcomes
Successful PTCA (%) 92.6 92.4 0.87
Residual stenosis (% 6 SD) 22.2 6 24.8 21.3 6 24.4 0.37
Elastic recoil (%) 4.6 2.8 0.04
Dissection (%) 30.2 25.0 0.01
Intracoronary thrombus (%) 2.8 2.8 1.00
Table 3. Clinical Endpoints
Clinical Endpoints
Iomeprol
(n 5 1,001)
Ioxaglate
(n 5 999) p
Abrupt closure in laboratory (%) 29 (2.9) 30 (3.0) 0.90
Abrupt closure out of laboratory (%) 31 (3.1) 41 (4.1) 0.23
Emergency bypass surgery (%) 8 (0.8) 7 (0.7) 0.82
Myocardial infarction, CK increase (%) 11 (1.1) 11 (1.1) 1.00
Myocardial infarction, Q-wave (%) 7 (0.7) 9 (0.9) 0.63
Cardiac death (%) 2 (0.2) 2 (0.2) 1.00
Major adverse cardiac events 28 29
Patients with MACE (%) 23 (2.3) 23 (2.3) 1.00
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DISCUSSION
Coronary angioplasty, abrupt vessel closure and major
adverse cardiac events. Abrupt vessel closure, usually as-
sociated with flow-limiting intimal flaps or medial dissec-
tions after coronary angioplasty, has remained an important
complication since PTCA was introduced by Gru¨ntzig et al.
in 1977 (19). Depending on the definition employed, the
reported incidence has been variable, ranging from 2.0% to
8.3% and, notably, has not appreciably diminished over the
past two decades (20–22). The most common angiographic
feature is that of obstructive coronary dissection, with an
incidence ranging from 35% to 80% (23). The presence of
intraluminal thrombus has been detected in up to 44% of
patients with coronary occlusion, often superimposed upon
medial dissection (24).
There are many factors, both clinical (coronary anatomy,
myocardium at risk, lesion morphology, stable/unstable
angina/acute myocardial infarction) and technical (pretreat-
ment with aspirin, heparin dose, use of glycoprotein IIb/IIIa
inhibitors and stents) that may affect the incidence of abrupt
closure and major ischemic events after coronary angio-
plasty. These considerations outline the difficulties in com-
paring the outcomes of trials that have been designed to
investigate the effects of nonionic and ionic contrast media
on abrupt vessel closure and ischemic complications after
coronary angioplasty.
Previous reports on nonionic versus ionic contrast media
and PTCA complications. Thus far, six randomized pro-
spective clinical trials comparing nonionic and ionic contrast
media in patients undergoing both elective and emergency
coronary angioplasty have been published (Table 4). In four
of these trials, the incidence of abrupt vessel closure,
coronary thrombosis or platelet deposition on guide wire
was lower with the ionic contrast medium (13–15,17). No
significant differences with respect to major ischemic com-
plications were observed between both types of contrast
media in five of these six trials (12–15,17). Only in one
study was a significant difference in post-PTCA ischemic
events observed; despite a comparable angiographic out-
come in both groups, the need for urgent recatheterization
(p 5 0.02) and re-PTCA (p 5 0.06) was less frequent in
patients allocated to receive the ionic agent (16).
Comparison with present data. More patients were en-
rolled in the present study than in the six previously
published trials combined (n 5 1,963). In these 2,000
patients undergoing predominantly elective coronary angio-
plasty, the incidence of abrupt vessel closure (events occur-
ring in laboratory and out of laboratory combined) was
6.5%, and the incidence of major ischemic complications
(myocardial infarction, emergent bypass surgery and cardiac
death combined) was 2.8%. Except for severe allergic
reactions requiring therapy that occurred only after the ionic
compound, there were no significant differences between
patients randomized to receive either the nonionic contrast
medium (iomeprol) or the ionic agent (ioxaglate).
In consideration of the baseline clinical and angiographic
data, the patients enrolled in the present study were closely
comparable with the patient population of Piessens et al.
Figure 1. Point estimates of percent patients and 95% confidence
limits for abrupt closure in laboratory among the patient sub-
groups.
Figure 2. Point estimates of percent patients and 95% confidence
limits for abrupt closure out-of-laboratory among the patient
subgroups.
Figure 3. Point estimates of percent patients and 95% confidence
limits for major adverse cardiac events among the patient sub-
groups.
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Table 4. Randomized Trials Comparing the Effects of Ionic Versus Nonionic Contrast Media in Patients Undergoing Coronary Angioplasty
Author
Year
Ref.
Contrast
Medium
Patients
Ionic
Nonionic
Stable
Unstable
Acute MI Heparin Dose (IU) Endpoints
Patients (n) With
Endpoints
Ionic vs/Nonionic
p Values
Ionic vs.
Nonionic Conclusion of the Authors
Lembo PTCA 5 1058 22.6% 10,000 bolus arrythmia 14 vs 5 0.045 “. . . nonionic contrast medium reduces
1991 diatrizoate n 5 507 74.3% 5,000 after . 1 h allergy 0 vs 1 NS overall incidence of serious ventricular
#12 iopamidol n 5 551 3.1% MACE 55 vs 55 NS arrhythmias but not the frequency of
myocardial infarction, the need for surgery,
or death.”
Esplugas n 5 100 32% 10,000 Bolus thrombus i.c. 1 vs 11 , 0.005 . . . “, compared with . . . ioxaglate, the
1991 ioxaglate n 5 50 68% 2,500 after . 2 h thrombus g.w. 1 vs 6 NS nonionic low osmolar contrast agent
#13 iohexol n 5 50 0% MACE 1 vs 2 NS iohexol increases the incidence of
thrombus during coronary angioplasty.”
Piessens n 5 500 60% 10,000 Bolus Closure i.lab. 8 vs 18 0.044 “With multivariate analysis, use of the
1993 ioxaglate n 5 250 40% 1,000 IU/h Closure o.lab 18 vs 14 NS nonionic agent rather than the ionic agent
#14 iohexol n 5 250 0% infusion MACE 7 vs 8 NS emerged as an independent predictor of
acute in-laboratory re-thrombosis.”
Lefevre n 5 64 100% 10,000 bolus % area of g.w. 24.1 6 5.7% vs “This in vivo study . . . confirms that of the
1994 ioxaglate n 5 32 — with thrombus 52.3 6 7.0% 0.004 two low osmolality contrast media the
#15 iopamidol n 5 32 — MACE 1 vs 2 NS antithrombogenic effect of the ionic
product is greater than that of the
nonionic product.”
Grines n 5 211 — 5,000–10,000 bolus, re-catheterization 3.0% vs 11.4% 0.02 “. . . in patients with unstable ischemic
1996 ioxaglate n 5 106 57.4% infusion 1,000/h re-PTCA 1.0% vs 5.8% NS syndromes undergoing coronary
#16 iopamidol n 5 105 42.6% MACE 5.8% vs 9.6% NS angioplasty, the use of ionic low osmolar
contrast medium reduces the risk of
ischemic complications . . .”
Qureshi n 5 30 — 5,000–10,000 bolus new thrombus 5 vs 11 0.028 “Nonionic low osmolality contrast medium
1997 ioxaglate n 5 15 100% total Thrombus 25 vs 27 NS was associated with significantly more
#17 iopamidol n 5 15 — MACE no data provided ? patients developing angioscopically visible
new thrombus.”
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(14). However, we have used a higher initial heparin-dose
(20,000 IU vs 10,000 IU), and stents were implanted in 574
of 2,441 coronary lesions, while Piessens did not use
intracoronary stenting at all. The incidence of abrupt closure
was lower in the present study (6.5% vs 10.2%), and major
ischemic events occurred less frequently (2.8% vs 3.0%).
Whether these observed differences between both trials are
due to clinical or technical reasons is not easy to determine.
Most probably, they are attributable to the deliberate but
consequent use of coronary stents in case of dissection or
unsatisfactory angiographic results.
Recent data of Aguirre et al. (25) are in agreement with
our findings. A meta-analysis of the 30-d composite end-
point (death, myocardial infarction, urgent re-intervention)
among 5,129 patients enrolled in the EPIC, EPILOG, and
CAPTURE trials receiving either nonionic or ionic contrast
media revealed no difference between both types of agents
(8.5% (nonionic) vs. 8.4% (ionic); p 5 0.98). Abciximab
significantly reduced event rates by a similar magnitude
regardless of nonionic or ionic contrast medium use.
Limitations and possible concerns. The activated clotting
time was not measured routinely in all patients. There is a
patient variability in heparin response (6). In preliminary
investigations carried out previously in our catheterization
laboratory, we have found an activated clotting time of
.350 seconds in virtually all patients receiving a bolus of
20,000 units of heparin. Since then, we have adopted this
regimen as a clinical routine for several years. These obser-
vations are in agreement with data of Murkherjee et al. (26).
In patients undergoing PTCA, they found complete aboli-
tion of the influence of both nonionic and ionic contrast
media on thrombin generation after a bolus injection of
20,000 units of heparin. Therefore, adequacy of hepariniza-
tion was presumably achieved in our patients, although
activated clotting times were not monitored routinely.
Post-PTCA creatine kinase levels were measured only in
symptomatic patients or when electrocardiographic changes
occurred, and the patients were followed only until hospital
discharge but not subsequently. Therefore, the “true” inci-
dence of myocardial infarction may have been underesti-
mated. On the other hand, less than 20% of our patients had
unstable angina or myocardial infarction, and more than
70% of all target lesions were ACC/AHA type A and type
B. The average clinical risk of our patients may have been
lower than in other trials focusing on high-risk coronary
interventions but may well reflect the clinical routine of
high-volume institutions. Additionally, the technical factors
mentioned above (heparin dose and stent implantation) also
may have contributed to this comparatively low figure of
ischemic complications.
Intracoronary fibrinolytics were used more frequently in
the nonionic contrast medium group. Although this was not
predefined as an endpoint of this study, the data require
some consideration. Fibrinolytics were used before balloon
inflation in eight patients in the nonionic contrast medium
group, as compared with only two patients in the ionic
group. This difference was apparently due to the higher
incidence of intracoronary thrombus in patients allocated to
receive the nonionic agent (4.2% vs 2.7%). After balloon
angioplasty, six patients in the nonionic group and two
patients in the ionic group were treated with fibrinolytics,
and the incidence of intracoronary thrombus was 2.8% in
either group. As compared with pre-PTCA, the incidence
decreased by 1.4% with the nonionic contrast medium but
increased by 0.1% with use of the ionic agent.
Intracoronary stents were also used more frequently in
patients randomized to receive the nonionic contrast me-
dium (31.6% vs 25.7%). They were used predominantly for
treatment of dissection or an unsatisfactory angiographic
result after balloon angioplasty. The incidence of dissection
(30.2% vs 25.0%) as well as elastic recoil (4.6% vs 2.8%) was
higher in the nonionic contrast medium group. It is,
however, very unlikely that contrast media have any impact
on dissections and recoil after balloon dilatation. On the
other hand, the nonionic contrast medium had a higher
iodine concentration (350 mg vs 320 mg). It is therefore
conceivable that in the ionic contrast medium group fewer
dissections were detected because of poorer opacification of
the target lesion. A subgroup analysis of patients with and
without intracoronary stents revealed no differences in the
incidence of abrupt closure and major adverse cardiac events
between both contrast medium groups. In other words, even
if patients with stents would have been excluded from the
analysis, contrast media was not an important factor in
altering clinical events.
Conclusions. Nonionic contrast media are weaker antico-
agulants than ionic compounds. Some authors have claimed
even procoagulant properties, and questions have been
raised as to the potential role of nonionic contrast agents in
the development of acute coronary thrombosis during cor-
onary angioplasty. The data presented here do not support
this theory. No differences between the nonionic (iomeprol)
and ionic contrast medium (ioxaglate) were observed with
regard to angiographic and clinical endpoints. The observed
in vitro differences between nonionic and ionic contrast
media seem to be insignificant under clinical conditions.
However, allergic side effects requiring treatment occurred
only in the ionic contrast medium group. It is concluded
that nonionic contrast media do not increase the risk of
thrombotic complications but minimize the risk of allergic
reactions in patients undergoing coronary interventions.
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